Medical Condition News

RSS

Low vitamin D levels may predispose one to type 2 diabetes

A new study shows that people with lower vitamin D levels were more likely to be obese and have higher degrees of insulin resistance, when the hormone becomes less effective at lowering blood sugar.

6 Dec 2011

Dust storms have adverse effect on hospital EDs for COPD

A new study published in the journal Respirology reveals that dust storms have an adverse effect on emergency hospital admission for chronic lung disease, often known as chronic obstructive pulmonary disease.

6 Dec 2011

Tips to keep kids safe during cold-weather

Cold winds, icy rain and, in some places, snow—Old Man Winter has arrived. His entry reminds us to get our furnaces checked and winterize our car, but what about the kids? "Children are even more vulnerable than adults to cold-weather and winter-related injuries," said Dr. Karen Judy, pediatrician at Loyola University Health System and professor of pediatrics at Loyola University Chicago Stritch School of Medicine.

6 Dec 2011

Top-line primary endpoint data from Pfizer's Toviaz trial on overactive bladder

Pfizer Inc. announced today the top-line primary endpoint result for Toviaz (fesoterodine fumarate) Study A0221049 - Efficacy and Safety of Fesoterodine Flexible Dose Regimen in Vulnerable Elderly Patients with Overactive Bladder.

6 Dec 2011

Acupuncture for chemotherapy-induced peripheral neuropathy

Acupuncture may help ease the severe nerve pain associated with certain cancer drugs, suggests a small preliminary study published in Acupuncture in Medicine.

5 Dec 2011

DFG to establish eight new CRCs as of 1 January 2012

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) will establish eight Collaborative Research Centres (CRC) as of 1 January 2012. This was agreed by the responsible Grants Committee at its autumn meeting in Bonn.

5 Dec 2011

Enrollment commences in Estech's HISTORIC-AF staged hybrid ablation study

Estech, a leader in minimally invasive cardiac surgery, announced today that the first three patients have been enrolled in the HISTORIC-AF European multi-center staged hybrid ablation clinical study.

5 Dec 2011

Biogen, Samsung partner to develop and market biosimilars

Samsung and Biogen Idec today announced that they have entered into an agreement to invest $300 million to establish a joint venture to develop, manufacture and market biosimilars. Samsung will take a leading role in the joint venture, with Biogen Idec contributing its expertise in protein engineering and biologics manufacturing.

5 Dec 2011

EnVivo presents positive EVP-6124 Phase 2b trial data on schizophrenia at 50th ACNP meeting

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it is presenting the comprehensive analysis of a recently completed Phase 2b clinical trial of EVP-6124, a novel, orally bioavailable nicotinic alpha-7 agonist, in schizophrenia at the American College of Neuropsychopharmacology 50th Anniversary Annual Meeting.

5 Dec 2011

Alcohol related liver problems on the rise among the young

According to the NHS figures there has been a huge increase in the number of young adults treated in hospital for serious liver problems brought on by drinking too much.

5 Dec 2011

Factors associated with increased risk of in-hospital falls after total hip or knee replacement surgery

Investigators from Hospital for Special Surgery have identified factors that are associated with an increased risk of in-hospital falls after total hip or knee replacement surgery.

5 Dec 2011

Preliminary top-line results from XenoPort's XP21279 Phase 2 trial for advanced Parkinson’s disease

XenoPort, Inc. announced today preliminary top-line results of a Phase 2, randomized, crossover clinical trial that compared optimized treatment with either Sinemet (immediate-release levodopa/carbidopa) or XP21279 co-formulated with carbidopa (279/CD) in advanced Parkinson's disease patients with motor fluctuations.

5 Dec 2011

Spacelabs Healthcare ranked top for Holter Monitoring solutions

According to MD Buyline's third quarter 2011 report, Spacelabs Healthcare is ranked #1 in overall customer satisfaction - having earned the industry's highest rating in all categories, including product performance, reliability, installation, implementation and applications training, as well as service response time and service repair quality - as related to Holter Monitoring solutions.

5 Dec 2011

NanoViricides submits pre-IND Meeting Request for FluCide to FDA

NanoViricides, Inc. announced today that it has submitted a pre-IND Meeting Request to the US FDA. The Company has requested an initial meeting with the US FDA to review the Company's proposed strategy and plan for conducting safety/toxicology studies and human clinical trials required for approval of its anti-influenza clinical drug candidate, FluCide™ (i.e. NV-INF-1).

5 Dec 2011

Growth hormone PDGF-BB and blood protein EPO implicated in development of cancer

Researchers at the Swedish medical university Karolinska Institutet have demonstrated that a growth hormone, PDGF-BB, and the blood protein EPO are involved in the development of cancer tumours and that they combine to help the tumours proliferate in the body.

5 Dec 2011

Converting patients to lamotrigine extended-release for epilepsy treatment found effective and safe

Epilepsy drug-switching study shows that using more ethical control groups could be the way forward for testing both drug efficacy and safety

5 Dec 2011

Targacept commences two clinical studies of TC-5619 for schizophrenia and ADHD

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced the initiation of two clinical studies of TC-5619, a Phase 2b study evaluating the product candidate as a treatment for negative symptoms and cognitive dysfunction in schizophrenia and a Phase 2 study evaluating the product candidate in adults as a treatment for attention deficit/hyperactivity disorder (ADHD), inattentive-predominant.

5 Dec 2011

Review highlights importance of examining totality of evidence prior to use of CPRs in clinical practice

Research carried out by the HRB Centre for Primary Care Research, based in the Royal College of Surgeons in Ireland (RCSI), recently published in the journal Family Practice aims to help patients that have suffered a transient ischaemic attack (TIA), otherwise known as a "mini-stroke" by assessing their risk of subsequent stroke.

5 Dec 2011

Zalicus commences Z160 Phase 1 clinical trial for pain

Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the initiation of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of a new formulation of Z160 (formerly NMED-160), a novel oral N-type calcium channel blocker.

5 Dec 2011

Spectrum seeks FDA IND approval for SPI-014 to treat hyperphosphatemia

Spectrum Pharmaceuticals today announced that it has submitted an investigational new drug (IND) application to the U.S. Food & Drug Administration for SPI-014 (previously referred to as RENAZORB), a second-generation lanthanum-based nanoparticle phosphate binding agent, that has the potential to treat hyperphosphatemia in patients with Stage 5 chronic kidney disease, or end-stage renal disease (ESRD).

5 Dec 2011